Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ESRRG | P62508 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylenediamine SCHEMBL1543305 | 0.98 | HTT (0.59) | HTTNPC1HPGDHSD17B10NAAA | |
| SCHEMBL11411958 | 0.90 | TSHR (0.59) | HTTNPC1HPGDHSD17B10NAAA | |
| SCHEMBL11407944 | 0.90 | TSHR (0.59) | HTTNPC1HPGDHSD17B10NAAA | |
| SCHEMBL1754800 | 0.89 | TSHR (0.67) | HTTNPC1HPGDHSD17B10NAAA | |
| SCHEMBL5707054 | 0.88 | HTT (0.69) | HTTNPC1HPGDHSD17B10NAAA | |
| SCHEMBL3861140 | 0.88 | TSHR (0.60) | HTTNPC1HPGDMAPTTSHR | |
| SCHEMBL31119120 | 0.88 | HTT (0.69) | HTTNPC1HPGDHSD17B10NAAA | |
| SCHEMBL31119121 | 0.88 | HTT (0.69) | HTTNPC1HPGDHSD17B10NAAA | |
| Hydrochloric Acid SCHEMBL15769882 | 0.86 | HTT (0.67) | HTTNPC1HPGDHSD17B10NAAA | |
| SCHEMBL8346286 | 0.86 | HTT (0.67) | HTTNPC1HPGDHSD17B10NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169905-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210145852-A1 | Combination Therapies for Treating Muscular Dystrophy | SAREPTA THERAPEUTICS INC (US) | 2021-05-20 | — | — | US | disclosed |
| US-20200254002-A1 | COMBINATION THERAPIES FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | US | disclosed |
| US-20200248178-A1 | COMBINATION THERAPIES FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS INC (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200046738-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| EP-2813486-B1 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2315740-B1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9708245-B2 | Fatty acid acylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070141022-A1 | POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS | EMISPHERE TECHNOLOGIES, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7208483-B2 | Polymeric delivery agents and delivery agent compounds | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| EP-1675859-A1 | MODULATORS OF SEROTONIN RECEPTORS | Bristol-Myers Squibb Company (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005035533-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
| US-5969171-A | Metal complexes as bleach activators | CLARIANT GMBH (DE) | 1999-10-19 | — | — | US | disclosed |
| EP-0889050-A2 | Metal complexes as bleach activators | Clariant GmbH (DE) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046738-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | HTT 1549/4885NPC1 410/4885HPGD 510/4885 |
| US-20070141022-A1 | POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS | LPXN, PGF, TTPA | HTT 713/4885NPC1 109/4885HPGD 583/4885 |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | HTT 2172/4885NPC1 2394/4885HPGD 683/4885 |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | HTT 1549/4885NPC1 410/4885HPGD 510/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | HTT 944/4885NPC1 371/4885HPGD 2494/4885 |
| US-20210169905-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | HTT 1549/4885NPC1 410/4885HPGD 510/4885 |
| US-20200254002-A1 | COMBINATION THERAPIES FOR TREATING MUSCULAR DYSTROPHY | UTRN, MBNL1, TNNC1 | HTT 1628/4885NPC1 3745/4885HPGD 1924/4885 |
| US-20200248178-A1 | COMBINATION THERAPIES FOR TREATING MUSCULAR DYSTROPHY | UTRN, MBNL1, TNNC1 | HTT 1628/4885NPC1 3745/4885HPGD 1924/4885 |
| US-20210145852-A1 | Combination Therapies for Treating Muscular Dystrophy | UTRN, MBNL1, TNNC1 | HTT 1628/4885NPC1 3745/4885HPGD 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.